{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:01:33Z","timestamp":1788012093509,"version":"build-2784847793"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Precision Cancer Consortium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-026-00416-z","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T03:35:06Z","timestamp":1771385706000},"page":"389-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology"],"prefix":"10.1007","volume":"14","author":[{"given":"Jamie P.","family":"Grossman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuofan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalene","family":"Crabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh S.","family":"Punekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"9","key":"416_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060326","volume":"12","author":"N Brew-Sam","year":"2022","unstructured":"Brew-Sam N, Parkinson A, Lueck C, et al. The current understanding of precision medicine and personalised medicine in selected research disciplines: study protocol of a systematic concept analysis. BMJ Open. 2022;12(9):e060326. https:\/\/doi.org\/10.1136\/bmjopen-2021-060326.","journal-title":"BMJ Open"},{"issue":"2","key":"416_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s41649-021-00165-3","volume":"13","author":"S Ong","year":"2021","unstructured":"Ong S, Ling J, Ballantyne A, Lysaght T, Xafis V. Perceptions of \u201cprecision\u201d and \u201cpersonalised\u201d medicine in Singapore and associated ethical issues. Asian Bioethics Rev. 2021;13(2):179\u201394. https:\/\/doi.org\/10.1007\/s41649-021-00165-3.","journal-title":"Asian Bioethics Rev"},{"issue":"5","key":"416_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3322\/caac.21844","volume":"74","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Gouda MA, Ryll B, Burris HA 3rd, Kurzrock R. The evolving landscape of tissue-agnostic therapies in precision oncology. CA Cancer J Clin. 2024;74(5):433\u201352. https:\/\/doi.org\/10.3322\/caac.21844.","journal-title":"CA Cancer J Clin"},{"key":"416_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc.2016.35","volume":"16","author":"H Carr","year":"2016","unstructured":"Carr H, McEwen R, Dougherty B, et al. Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer. 2016;16:319\u201329. https:\/\/doi.org\/10.1038\/nrc.2016.35.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"416_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002.","journal-title":"J Mol Diagn"},{"issue":"11","key":"416_CR6","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491\u2013505. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014.","journal-title":"Ann Oncol"},{"issue":"9","key":"416_CR7","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29(9):1895\u2013902. https:\/\/doi.org\/10.1093\/annonc\/mdy263.","journal-title":"Ann Oncol"},{"issue":"16","key":"416_CR8","doi-asserted-by":"publisher","first-page":"4389.e15","DOI":"10.1016\/j.cell.2024.05.039","volume":"187","author":"SR Savage","year":"2024","unstructured":"Savage SR, Yi X, Lei JT, et al. Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell. 2024;187(16):4389-4407.e15. https:\/\/doi.org\/10.1016\/j.cell.2024.05.039.","journal-title":"Cell"},{"issue":"4","key":"416_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.6004\/jadpro.2020.11.4.9","volume":"11","author":"DB Dunn","year":"2020","unstructured":"Dunn DB. Larotrectinib and entrectinib: TRK inhibitors for the treatment of pediatric and adult patients with NTRK gene fusion. J Adv Pract Oncol. 2020;11(4):418\u201323. https:\/\/doi.org\/10.6004\/jadpro.2020.11.4.9.","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"416_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2302299","volume":"390","author":"A Drilon","year":"2024","unstructured":"Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2302299.","journal-title":"N Engl J Med"},{"issue":"18","key":"416_CR11","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","volume":"29","author":"ES Duke","year":"2023","unstructured":"Duke ES, Bradford D, Marcovitz M, et al. FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors. Clin Cancer Res. 2023;29(18):3573\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0459.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"416_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0738-1","volume":"12","author":"P Zhao","year":"2019","unstructured":"Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54. https:\/\/doi.org\/10.1186\/s13045-019-0738-1.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"416_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731\u201347. https:\/\/doi.org\/10.1038\/s41571-018-0113-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"416_CR14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","volume":"7","author":"KZ Thein","year":"2021","unstructured":"Thein KZ, Velcheti V, Mooers BHM, Wu J, Subbiah V. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021;7(12):1074\u201388. https:\/\/doi.org\/10.1016\/j.trecan.2021.07.003.","journal-title":"Trends Cancer"},{"issue":"7","key":"416_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","volume":"20","author":"S Du","year":"2023","unstructured":"Du S, Zhang Y, Xu J. Current progress in cancer treatment by targeting FGFR signaling. Cancer Biol Med. 2023;20(7):490\u20139. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0137.","journal-title":"Cancer Biol Med"},{"key":"416_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071823","author":"I Proietti","year":"2020","unstructured":"Proietti I, Skroza N, Michelini S, et al. BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12071823.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"416_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100336","volume":"7","author":"M Palmeri","year":"2022","unstructured":"Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7(1):100336. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100336.","journal-title":"ESMO Open"},{"issue":"1","key":"416_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.20892\/j.issn.2095-3941.2018.0055","volume":"16","author":"D Qin","year":"2019","unstructured":"Qin D. Next-generation sequencing and its clinical application. Cancer Biol Med. 2019;16(1):4\u201310. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0055.","journal-title":"Cancer Biol Med"},{"issue":"3","key":"416_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/mgg3.201","volume":"4","author":"J Xie","year":"2016","unstructured":"Xie J, Lu X, Wu X, et al. Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. Mol Genet Genom Med. 2016;4(3):262\u201372. https:\/\/doi.org\/10.1002\/mgg3.201.","journal-title":"Mol Genet Genom Med"},{"issue":"2","key":"416_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/jpm5020165","volume":"5","author":"RT Hillman","year":"2015","unstructured":"Hillman RT, Ward K, Saenz C, McHale M, Plaxe S. Barriers prevent patient access to personalized therapies identified by molecular tumor profiling of gynecologic malignancies. J Pers Med. 2015;5(2):165\u201373. https:\/\/doi.org\/10.3390\/jpm5020165.","journal-title":"J Pers Med"},{"key":"416_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12907-015-0020-6","volume":"15","author":"R Arsenic","year":"2015","unstructured":"Arsenic R, Treue D, Lehmann A, et al. Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clin Pathol. 2015;15:20. https:\/\/doi.org\/10.1186\/s12907-015-0020-6.","journal-title":"BMC Clin Pathol"},{"key":"416_CR22","doi-asserted-by":"publisher","unstructured":"Ghosh M, Lingaraju SM, C RK, et al. Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: a single institutional experience. Sci Rep. 2025;15(1):12455. https:\/\/doi.org\/10.1038\/s41598-025-94762-z.","DOI":"10.1038\/s41598-025-94762-z"},{"issue":"1","key":"416_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/jalm\/jfad091","volume":"9","author":"MY Tjota","year":"2024","unstructured":"Tjota MY, Segal JP, Wang P. Clinical utility and benefits of comprehensive genomic profiling in cancer. J Appl Lab Med. 2024;9(1):76\u201391. https:\/\/doi.org\/10.1093\/jalm\/jfad091.","journal-title":"J Appl Lab Med"},{"key":"416_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2024.09.001","author":"LJ Hung","year":"2024","unstructured":"Hung LJ, Huang CY, Tung KC, et al. Comprehensive genomic profiling in multiple cancer types: a comparative analysis of the National Biobank Consortium of Taiwan and clinical practice cohorts. J Formos Med Assoc. 2024. https:\/\/doi.org\/10.1016\/j.jfma.2024.09.001.","journal-title":"J Formos Med Assoc"},{"key":"416_CR25","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1200\/edbk_160391","volume":"36","author":"F Lynce","year":"2016","unstructured":"Lynce F, Isaacs C. How far do we go with genetic evaluation? Gene, panel, and tumor testing. Am Soc Clin Oncol Educ Book. 2016;36:e72\u20138. https:\/\/doi.org\/10.1200\/edbk_160391.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"416_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1445668","author":"KC Strickland","year":"2024","unstructured":"Strickland KC, Nesline MK, Previs RA, et al. Case report: single gene testing and comprehensive genomic profiling in non-small cell lung cancer\u2014a case series of divergent results from a large reference laboratory. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1445668.","journal-title":"Front Oncol"},{"key":"416_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.05.579012","author":"JX Chong","year":"2024","unstructured":"Chong JX, Berger SI, Baxter S, et al. Considerations for reporting variants in novel candidate genes identified during clinical genomic testing. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.02.05.579012.","journal-title":"bioRxiv"},{"issue":"3","key":"416_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cll.2022.05.001","volume":"42","author":"M Hanbazazh","year":"2022","unstructured":"Hanbazazh M, Morlote D, Mackinnon AC, Harada S. Utility of single-gene testing in cancer specimens. Clin Lab Med. 2022;42(3):385\u201394. https:\/\/doi.org\/10.1016\/j.cll.2022.05.001.","journal-title":"Clin Lab Med"},{"issue":"4","key":"416_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.7150\/ijms.101219","volume":"22","author":"CL Lee","year":"2025","unstructured":"Lee CL, Chuang CK, Chiu HC, et al. Understanding genetic screening: harnessing health information to prevent disease risks. Int J Med Sci. 2025;22(4):903\u201319. https:\/\/doi.org\/10.7150\/ijms.101219.","journal-title":"Int J Med Sci"},{"issue":"4","key":"416_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2017-03-734533","volume":"130","author":"FC Kuo","year":"2017","unstructured":"Kuo FC, Mar BG, Lindsley RC, Lindeman NI. The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood. 2017;130(4):433\u20139. https:\/\/doi.org\/10.1182\/blood-2017-03-734533.","journal-title":"Blood"},{"issue":"1","key":"416_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2156-14-6","volume":"14","author":"ELH Chin","year":"2013","unstructured":"Chin ELH, da Silva C, Hegde M. Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations. BMC Genet. 2013;14(1):6. https:\/\/doi.org\/10.1186\/1471-2156-14-6.","journal-title":"BMC Genet"},{"issue":"4","key":"416_CR32","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s12253-020-00844-w","volume":"26","author":"D Niu","year":"2020","unstructured":"Niu D, Li L, Yu Y, et al. Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers. Pathol Oncol Res. 2020;26(4):2577\u201385. https:\/\/doi.org\/10.1007\/s12253-020-00844-w.","journal-title":"Pathol Oncol Res"},{"key":"416_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","volume":"176","author":"N Normanno","year":"2022","unstructured":"Normanno N, Apostolidis K, Wolf A, et al. Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer. 2022;176:70\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.005.","journal-title":"Eur J Cancer"},{"issue":"7","key":"416_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588\u2013606. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005.","journal-title":"Ann Oncol"},{"key":"416_CR35","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer, Version 1 (2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pd."},{"key":"416_CR36","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3 (2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"416_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12010072","author":"D Horgan","year":"2022","unstructured":"Horgan D, Curigliano G, Riess O, et al. Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12010072.","journal-title":"J Pers Med"},{"key":"416_CR38","doi-asserted-by":"publisher","unstructured":"AB DAL, Seo MK. Has the development of cancer biomarkers to guide treatment improved health outcomes? Eur J Health Econ. 2021;22(5):789\u2013810. https:\/\/doi.org\/10.1007\/s10198-021-01290-4.","DOI":"10.1007\/s10198-021-01290-4"},{"key":"416_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.18.00356","volume":"3","author":"NA Pennell","year":"2019","unstructured":"Pennell NA, Mutebi A, Zhou ZY, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1\u20139. https:\/\/doi.org\/10.1200\/po.18.00356.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"416_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s41669-020-00249-0","volume":"5","author":"G Pruneri","year":"2021","unstructured":"Pruneri G, De Braud F, Sapino A, et al. Next-generation sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach? PharmacoEcon Open. 2021;5(2):285\u201398. https:\/\/doi.org\/10.1007\/s41669-020-00249-0.","journal-title":"PharmacoEcon Open"},{"issue":"9","key":"416_CR41","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","volume":"27","author":"M Mirza","year":"2024","unstructured":"Mirza M, Goerke L, Anderson A, Wilsdon T. Assessing the cost-effectiveness of next-generation sequencing as a biomarker testing approach in oncology and policy implications: a literature review. Value Health. 2024;27(9):1300\u20139. https:\/\/doi.org\/10.1016\/j.jval.2024.04.023.","journal-title":"Value Health"},{"issue":"3","key":"416_CR42","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3390\/curroncol31030103","volume":"31","author":"S Snow","year":"2024","unstructured":"Snow S, Brezden-Masley C, Carter MD, et al. Barriers and unequal access to timely molecular testing results: addressing the inequities in cancer care delays across Canada. Curr Oncol. 2024;31(3):1359\u201375. https:\/\/doi.org\/10.3390\/curroncol31030103.","journal-title":"Curr Oncol"},{"issue":"5","key":"416_CR43","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1093\/oncolo\/oyad005","volume":"28","author":"A Stenzinger","year":"2023","unstructured":"Stenzinger A, Cuffel B, Paracha N, et al. Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator. Oncologist. 2023;28(5):e242\u201353. https:\/\/doi.org\/10.1093\/oncolo\/oyad005.","journal-title":"Oncologist"},{"key":"416_CR44","unstructured":"Precision Cancer Consortium Website. https:\/\/www.precisioncancerconsortium.com\/.\nAccessed 4 July 2025."},{"issue":"1","key":"416_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2214\/ajr.184.1.01840014","volume":"184","author":"S Weinstein","year":"2005","unstructured":"Weinstein S, Obuchowski NA, Lieber ML. Clinical evaluation of diagnostic tests. AJR Am J Roentgenol. 2005;184(1):14\u20139. https:\/\/doi.org\/10.2214\/ajr.184.1.01840014.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"416_CR46","doi-asserted-by":"publisher","first-page":"20495","DOI":"10.1038\/s41598-022-23319-1","volume":"12","author":"YJ Kang","year":"2022","unstructured":"Kang YJ, O\u2019Haire S, Franchini F, et al. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. Sci Rep. 2022;12(1):20495. https:\/\/doi.org\/10.1038\/s41598-022-23319-1.","journal-title":"Sci Rep"},{"issue":"7","key":"416_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-015-0348-2","volume":"16","author":"H Kawakami","year":"2015","unstructured":"Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015;16(7):30. https:\/\/doi.org\/10.1007\/s11864-015-0348-2.","journal-title":"Curr Treat Options Oncol"},{"key":"416_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57941-0","author":"G Sledge","year":"2025","unstructured":"Sledge G, Yoshino T, Xiu J, et al. Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-57941-0.","journal-title":"Nat Commun"},{"key":"416_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101744","volume":"36","author":"M Nagasaka","year":"2023","unstructured":"Nagasaka M, Brazel D, Baca Y, et al. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. Transl Oncol. 2023;36:101744. https:\/\/doi.org\/10.1016\/j.tranon.2023.101744.","journal-title":"Transl Oncol"},{"issue":"3","key":"416_CR50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","volume":"21","author":"AJ Hanrahan","year":"2024","unstructured":"Hanrahan AJ, Chen Z, Rosen N, Solit DB. BRAF - a tumour-agnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol. 2024;21(3):224\u201347. https:\/\/doi.org\/10.1038\/s41571-023-00852-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"416_CR51","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, Wang X, Alessi JV, et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1981.","journal-title":"JAMA Oncol"},{"key":"416_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.608989","volume":"10","author":"Y Qiu","year":"2020","unstructured":"Qiu Y, Liu L, Yang H, et al. Integrating histologic and genomic characteristics to predict tumor mutation burden of early-stage non-small-cell lung cancer. Front Oncol. 2020;10:608989. https:\/\/doi.org\/10.3389\/fonc.2020.608989.","journal-title":"Front Oncol"},{"issue":"1","key":"416_CR53","doi-asserted-by":"publisher","DOI":"10.21037\/cco-23-117","volume":"13","author":"Y Huang","year":"2024","unstructured":"Huang Y, Jia W, Zhao G, et al. Clinical features and mutation analysis of class\u00a01\/2\/3 BRAF mutation colorectal cancer. Chin Clin Oncol. 2024;13(1):3. https:\/\/doi.org\/10.21037\/cco-23-117.","journal-title":"Chin Clin Oncol"},{"key":"416_CR54","unstructured":"Inflation tool\u2014value of 2021 Euro today\u2014inflation calculator. https:\/\/www.inflationtool.com\/euro\/2021-to-present-value?amount=218&year2=2024&frequency=yearly.\nAccessed 21 Feb 2025."},{"key":"416_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.semcancer.2021.08.002","volume":"84","author":"N Normanno","year":"2022","unstructured":"Normanno N, Apostolidis K, de Lorenzo F, et al. Cancer biomarkers in the era of precision oncology: addressing the needs of patients and health systems. Semin Cancer Biol. 2022;84:293\u2013301. https:\/\/doi.org\/10.1016\/j.semcancer.2021.08.002.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"416_CR56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000492783","volume":"8","author":"AJ Larner","year":"2018","unstructured":"Larner AJ. Number needed to diagnose, predict, or misdiagnose: useful metrics for non-canonical signs of cognitive status? Dement Geriatr Cogn Disord Extra. 2018;8(3):321\u20137. https:\/\/doi.org\/10.1159\/000492783.","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"416_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2021.101745","volume":"58","author":"TM Carvalho","year":"2021","unstructured":"Carvalho TM, Dourado RM, Nakatani SM, et al. Digital PCR detection of EGFR somatic mutations in non-small-cell lung cancer formalin fixed paraffin embedded samples. Mol Cell Probes. 2021;58:101745. https:\/\/doi.org\/10.1016\/j.mcp.2021.101745.","journal-title":"Mol Cell Probes"},{"issue":"2","key":"416_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00428-018-2486-y","volume":"474","author":"R Colling","year":"2019","unstructured":"Colling R, Bancroft H, Langman G, Soilleux E. Fully automated real-time PCR for EGFR testing in non-small cell lung carcinoma. Virchows Arch. 2019;474(2):187\u201392. https:\/\/doi.org\/10.1007\/s00428-018-2486-y.","journal-title":"Virchows Arch"},{"key":"416_CR59","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/385087","volume":"2013","author":"C Roma","year":"2013","unstructured":"Roma C, Esposito C, Rachiglio AM, et al. Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. Biomed Res Int. 2013;2013:385087. https:\/\/doi.org\/10.1155\/2013\/385087.","journal-title":"Biomed Res Int"},{"issue":"8","key":"416_CR60","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1089\/gtmb.2015.0069","volume":"19","author":"MA Zaki","year":"2015","unstructured":"Zaki MA, Ramadan RA, Mahmoud MI, El-Kaffash DM, Assaad RS. Nonenriched PCR versus mutant-enriched PCR in detecting selected epidermal growth factor receptor gene mutations among nonsmall-cell lung cancer patients. Genet Test Mol Biomark. 2015;19(8):444\u20139. https:\/\/doi.org\/10.1089\/gtmb.2015.0069.","journal-title":"Genet Test Mol Biomark"},{"issue":"61","key":"416_CR61","doi-asserted-by":"publisher","first-page":"103055","DOI":"10.18632\/oncotarget.21476","volume":"8","author":"M Ilie","year":"2017","unstructured":"Ilie M, Butori C, Lassalle S, et al. Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget. 2017;8(61):103055\u201362. https:\/\/doi.org\/10.18632\/oncotarget.21476.","journal-title":"Oncotarget"},{"issue":"4","key":"416_CR62","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1309\/ajcp40xetvyamjpy","volume":"143","author":"JW Hinrichs","year":"2015","unstructured":"Hinrichs JW, van Blokland WT, Moons MJ, et al. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice. Am J Clin Pathol. 2015;143(4):573\u20138. https:\/\/doi.org\/10.1309\/ajcp40xetvyamjpy.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"416_CR63","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4997\/jrcpe.2018.104","volume":"48","author":"YC Kheng","year":"2018","unstructured":"Kheng YC, Walsh K, Williams L, Wallace WA, Harrison DJ, Oniscu A. ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing. J R Coll Physicians Edinb. 2018;48(1):20\u20134. https:\/\/doi.org\/10.4997\/jrcpe.2018.104.","journal-title":"J R Coll Physicians Edinb"},{"issue":"2","key":"416_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171225","volume":"12","author":"Y Takase","year":"2017","unstructured":"Takase Y, Usui K, Shimizu K, et al. Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method. PLoS ONE. 2017;12(2):e0171225. https:\/\/doi.org\/10.1371\/journal.pone.0171225.","journal-title":"PLoS ONE"},{"issue":"1","key":"416_CR65","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.cllc.2018.10.004","volume":"20","author":"EK Kim","year":"2019","unstructured":"Kim EK, Kim KA, Lee CY, et al. Molecular diagnostic assays and clinicopathologic implications of MET exon 14 skipping mutation in non-small-cell lung cancer. Clin Lung Cancer. 2019;20(1):e123\u201332. https:\/\/doi.org\/10.1016\/j.cllc.2018.10.004.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"416_CR66","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00428-024-03778-9","volume":"484","author":"L Melchior","year":"2024","unstructured":"Melchior L, Hirschmann A, Hofman P, et al. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC. Virchows Arch. 2024;484(4):677\u201386. https:\/\/doi.org\/10.1007\/s00428-024-03778-9.","journal-title":"Virchows Arch"},{"key":"416_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100451","author":"C Xiang","year":"2024","unstructured":"Xiang C, Lv X, Chen K, et al. Unraveling the significance of MET focal amplification in lung cancer: integrative NGS, FISH, and IHC investigation. Mod Pathol. 2024. https:\/\/doi.org\/10.1016\/j.modpat.2024.100451.","journal-title":"Mod Pathol"},{"issue":"1","key":"416_CR68","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","volume":"33","author":"JP Solomon","year":"2020","unstructured":"Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38\u201346. https:\/\/doi.org\/10.1038\/s41379-019-0324-7.","journal-title":"Mod Pathol"},{"issue":"1","key":"416_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72809-7","volume":"10","author":"J Lung","year":"2020","unstructured":"Lung J, Hung MS, Lin YC, et al. A highly sensitive and specific real-time quantitative PCR for BRAF V600E\/K mutation screening. Sci Rep. 2020;10(1):16943. https:\/\/doi.org\/10.1038\/s41598-020-72809-7.","journal-title":"Sci Rep"},{"issue":"5","key":"416_CR70","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/jclinpath-2015-203345","volume":"69","author":"R Colling","year":"2016","unstructured":"Colling R, Wang LM, Soilleux E. Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: a diagnostic test accuracy study. J Clin Pathol. 2016;69(5):398\u2013402. https:\/\/doi.org\/10.1136\/jclinpath-2015-203345.","journal-title":"J Clin Pathol"},{"issue":"5","key":"416_CR71","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/1078-0432.Ccr-20-3208","volume":"27","author":"SR Yang","year":"2021","unstructured":"Yang SR, Aypar U, Rosen EY, et al. A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res. 2021;27(5):1316\u201328. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3208.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"416_CR72","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","volume":"20","author":"MF Press","year":"2002","unstructured":"Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L. Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20(14):3095\u2013105. https:\/\/doi.org\/10.1200\/JCO.2002.09.094.","journal-title":"J Clin Oncol"},{"issue":"3","key":"416_CR73","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s12020-015-0720-9","volume":"53","author":"C Martinuzzi","year":"2016","unstructured":"Martinuzzi C, Pastorino L, Andreotti V, et al. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer. Endocrine. 2016;53(3):672\u201380. https:\/\/doi.org\/10.1007\/s12020-015-0720-9.","journal-title":"Endocrine"},{"issue":"3","key":"416_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12376","volume":"10","author":"R Zago Baltazar","year":"2024","unstructured":"Zago Baltazar R, Claerhout S, Vander Borght S, et al. Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours. J Pathol Clin Res. 2024;10(3):e12376. https:\/\/doi.org\/10.1002\/2056-4538.12376.","journal-title":"J Pathol Clin Res"},{"issue":"4","key":"416_CR75","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00129039-200112000-00011","volume":"9","author":"GT McKee","year":"2001","unstructured":"McKee GT, Tambouret RH, Finkelstein D. A reliable method of demonstrating HER-2\/neu, estrogen receptors, and progesterone receptors on routinely processed cytologic material. Appl Immunohistochem Mol Morphol. 2001;9(4):352\u20137. https:\/\/doi.org\/10.1097\/00129039-200112000-00011.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"416_CR76","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1365-2559.2003.01598.x","volume":"42","author":"A Vincent-Salomon","year":"2003","unstructured":"Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology. 2003;42(4):337\u201347. https:\/\/doi.org\/10.1046\/j.1365-2559.2003.01598.x.","journal-title":"Histopathology"},{"issue":"14","key":"416_CR77","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1038\/sj.onc.1207361","volume":"23","author":"F Bertucci","year":"2004","unstructured":"Bertucci F, Borie N, Ginestier C, et al. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene. 2004;23(14):2564\u201375. https:\/\/doi.org\/10.1038\/sj.onc.1207361.","journal-title":"Oncogene"},{"issue":"1","key":"416_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/jcp.2006.043562","volume":"61","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase\u00a0II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol. 2008;61(1):89\u201394. https:\/\/doi.org\/10.1136\/jcp.2006.043562.","journal-title":"J Clin Pathol"},{"issue":"3","key":"416_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jso.21220","volume":"99","author":"HM Seo","year":"2009","unstructured":"Seo HM, Chang YS, Joo SH, et al. Clinicopathologic characteristics and outcomes of gastric cancers with the MSI-H phenotype. J Surg Oncol. 2009;99(3):143\u20137. https:\/\/doi.org\/10.1002\/jso.21220.","journal-title":"J Surg Oncol"},{"issue":"20","key":"416_CR80","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1158\/1078-0432.Ccr-11-1244","volume":"17","author":"TL Lotan","year":"2011","unstructured":"Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011;17(20):6563\u201373. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-1244.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"416_CR81","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/PAT.0b013e3283513e8b","volume":"44","author":"EY Cho","year":"2012","unstructured":"Cho EY, Srivastava A, Park K, et al. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology. 2012;44(3):216\u201320. https:\/\/doi.org\/10.1097\/PAT.0b013e3283513e8b.","journal-title":"Pathology"},{"issue":"3","key":"416_CR82","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3892\/or.2013.2229","volume":"29","author":"A Harl\u00e9","year":"2013","unstructured":"Harl\u00e9 A, Lion M, Lozano N, et al. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria. Oncol Rep. 2013;29(3):1043\u201352. https:\/\/doi.org\/10.3892\/or.2013.2229.","journal-title":"Oncol Rep"},{"issue":"8","key":"416_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070839","volume":"8","author":"YC Wu","year":"2013","unstructured":"Wu YC, Chang IC, Wang CL, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE. 2013;8(8):e70839. https:\/\/doi.org\/10.1371\/journal.pone.0070839.","journal-title":"PLoS ONE"},{"issue":"3","key":"416_CR84","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1634\/theoncologist.2014-0389","volume":"20","author":"M Pekar-Zlotin","year":"2015","unstructured":"Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015;20(3):316\u201322. https:\/\/doi.org\/10.1634\/theoncologist.2014-0389.","journal-title":"Oncologist"},{"issue":"3","key":"416_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117032","volume":"10","author":"L Liu","year":"2015","unstructured":"Liu L, Zhan P, Zhou X, et al. Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods. PLoS ONE. 2015;10(3):e0117032. https:\/\/doi.org\/10.1371\/journal.pone.0117032.","journal-title":"PLoS ONE"},{"issue":"1","key":"416_CR86","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.5301\/jbm.5000171","volume":"31","author":"JS Pyo","year":"2016","unstructured":"Pyo JS, Sohn JH, Kim WH. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. Int J Biol Mark. 2016;31(1):e1-10. https:\/\/doi.org\/10.5301\/jbm.5000171.","journal-title":"Int J Biol Mark"},{"issue":"11","key":"416_CR87","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","volume":"28","author":"E Valtorta","year":"2015","unstructured":"Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481\u201391. https:\/\/doi.org\/10.1038\/modpathol.2015.98.","journal-title":"Mod Pathol"},{"issue":"10","key":"416_CR88","first-page":"704","volume":"44","author":"Y Qin","year":"2015","unstructured":"Qin Y, Liang L, Zheng X, et al. Value of detection of DNA mismatch repair proteins deficiency by immunohistochemistry in predicting tumor microsatellite status. Zhonghua Bing Li Xue Za Zhi. 2015;44(10):704\u20138.","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"issue":"5","key":"416_CR89","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00428-016-1904-2","volume":"468","author":"CG Pican\u00e7o-Albuquerque","year":"2016","unstructured":"Pican\u00e7o-Albuquerque CG, Morais CL, Carvalho FL, et al. In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading. Virchows Arch. 2016;468(5):607\u201317. https:\/\/doi.org\/10.1007\/s00428-016-1904-2.","journal-title":"Virchows Arch"},{"issue":"8","key":"416_CR90","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/cas.13696","volume":"109","author":"T Shimoi","year":"2018","unstructured":"Shimoi T, Hamada A, Yamagishi M, et al. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer Sci. 2018;109(8):2558\u201366. https:\/\/doi.org\/10.1111\/cas.13696.","journal-title":"Cancer Sci"},{"issue":"1","key":"416_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5127-6","volume":"18","author":"M Jang","year":"2018","unstructured":"Jang M, Kwon Y, Kim H, et al. Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study. BMC Cancer. 2018;18(1):1218. https:\/\/doi.org\/10.1186\/s12885-018-5127-6.","journal-title":"BMC Cancer"},{"issue":"8","key":"416_CR92","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1373\/clinchem.2019.302315","volume":"65","author":"W Chen","year":"2019","unstructured":"Chen W, Zheng J, Wu C, et al. Breast cancer subtype classification using 4-plex droplet digital PCR. Clin Chem. 2019;65(8):1051\u20139. https:\/\/doi.org\/10.1373\/clinchem.2019.302315.","journal-title":"Clin Chem"},{"issue":"7","key":"416_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219204","volume":"14","author":"P Gilson","year":"2019","unstructured":"Gilson P, Franczak C, Dubouis L, et al. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and next-generation sequencing for laboratory workflow optimisation. PLoS ONE. 2019;14(7):e0219204. https:\/\/doi.org\/10.1371\/journal.pone.0219204.","journal-title":"PLoS ONE"},{"issue":"5","key":"416_CR94","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41374-021-00536-2","volume":"101","author":"N Piton","year":"2021","unstructured":"Piton N, Lanic M-D, Marguet F, et al. An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology. Lab Investig. 2021;101(5):648\u201360. https:\/\/doi.org\/10.1038\/s41374-021-00536-2.","journal-title":"Lab Investig"},{"issue":"5","key":"416_CR95","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jtho.2021.01.1619","volume":"16","author":"T Radonic","year":"2021","unstructured":"Radonic T, Geurts-Giele WRR, Samsom KG, et al. RET fluorescence in situ hybridization analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer. J Thorac Oncol. 2021;16(5):798\u2013806. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.1619.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"416_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10852-z","volume":"23","author":"M Chen","year":"2023","unstructured":"Chen M, Xue J, Sang Y, et al. Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer. BMC Cancer. 2023;23(1):363. https:\/\/doi.org\/10.1186\/s12885-023-10852-z.","journal-title":"BMC Cancer"},{"issue":"4","key":"416_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100653","volume":"5","author":"E Conde","year":"2024","unstructured":"Conde E, Hernandez S, Rodriguez Carrillo JL, et al. RET fusion testing in patients with NSCLC: the RETING study. JTO Clin Res Rep. 2024;5(4):100653. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100653.","journal-title":"JTO Clin Res Rep"},{"key":"416_CR98","unstructured":"MTRC. Merged 2024 R\u00e9f\u00e9rentiel des actes innovants hors nomenclature and supplementary list for IVD tests published in France. https:\/\/mtrconsult.com\/news\/merged-2024-rihn-and-supplementary-list-ivd-tests-published-france.\nAccessed 21 Feb 2025."},{"issue":"8","key":"416_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202865","volume":"13","author":"DH Lee","year":"2018","unstructured":"Lee DH, Tsao MS, Kambartel KO, et al. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: pivotal observational study. PLoS ONE. 2018;13(8):e0202865. https:\/\/doi.org\/10.1371\/journal.pone.0202865.","journal-title":"PLoS ONE"},{"issue":"6","key":"416_CR100","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/gim.2014.122","volume":"17","author":"Y Xue","year":"2015","unstructured":"Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome\/genome sequencing. Genet Med. 2015;17(6):444\u201351. https:\/\/doi.org\/10.1038\/gim.2014.122.","journal-title":"Genet Med"},{"issue":"1","key":"416_CR101","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmed.2022-0514","volume":"23","author":"C Morton","year":"2023","unstructured":"Morton C, Sarker D, Ross P. Next-generation sequencing and molecular therapy. Clin Med. 2023;23(1):65\u20139. https:\/\/doi.org\/10.7861\/clinmed.2022-0514.","journal-title":"Clin Med"},{"issue":"4","key":"416_CR102","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2217\/pme-2016-0104","volume":"14","author":"DA Messner","year":"2017","unstructured":"Messner DA, Koay P, Al Naber J, et al. Barriers to clinical adoption of next-generation sequencing: a policy Delphi panel\u2019s solutions. Per Med. 2017;14(4):339\u201354. https:\/\/doi.org\/10.2217\/pme-2016-0104.","journal-title":"Per Med"},{"key":"416_CR103","unstructured":"National Academies of Sciences Engineering, and Medicine, Health and Medicine Division, Board on Health Care Service, Roundtable on Genomics and Precision Health. The National Academies Collection: reports funded by National Institutes of Health. In: Beachy S, Hackmann M, Asalone K, Wizemann TM, editors. Realizing the potential of genomics across the continuum of precision health care: Proceedings of a workshop. Washington (DC): National Academies Press (US) Copyright 2023 by the National Academy of Sciences. National Academies of Sciences, Engineering, and Medicine and National Academies Press and the graphical logos for each are all trademarks of the National Academy of Sciences. All rights reserved; 2023."},{"key":"416_CR104","unstructured":"National Academies of Sciences Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health. The National Academies Collection: Reports funded by National Institutes of Health. Understanding Disparities in Access to Genomic Medicine: Proceedings of a workshop. Washington (DC): National Academies Press (US) Copyright 2018 by the National Academy of Sciences. All rights reserved; 2018."},{"issue":"7","key":"416_CR105","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/ijc.31542","volume":"143","author":"W Luo","year":"2018","unstructured":"Luo W, Tian P, Wang Y, et al. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers. Int J Cancer. 2018;143(7):1696\u2013705. https:\/\/doi.org\/10.1002\/ijc.31542.","journal-title":"Int J Cancer"},{"issue":"1","key":"416_CR106","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01816-9","volume":"16","author":"N Ghoreyshi","year":"2025","unstructured":"Ghoreyshi N, Heidari R, Farhadi A, et al. Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. Discov Oncol. 2025;16(1):578. https:\/\/doi.org\/10.1007\/s12672-025-01816-9.","journal-title":"Discov Oncol"},{"key":"416_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030493","author":"XM Pei","year":"2023","unstructured":"Pei XM, Yeung MHY, Wong ANN, et al. Targeted sequencing approach and its clinical applications for the molecular diagnosis of human diseases. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12030493.","journal-title":"Cells"},{"issue":"4","key":"416_CR108","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jval.2021.09.017","volume":"25","author":"OM Dong","year":"2022","unstructured":"Dong OM, Poonnen PJ, Winski D, et al. Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma. Value Health. 2022;25(4):582\u201394. https:\/\/doi.org\/10.1016\/j.jval.2021.09.017.","journal-title":"Value Health"},{"key":"416_CR109","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00294","volume":"7","author":"CA Lemmon","year":"2023","unstructured":"Lemmon CA, Zhou J, Hobbs B, Pennell NA. Modeling costs and life-years gained by population-wide next-generation sequencing or single-gene testing in nonsquamous non-small-cell lung cancer in the United States. JCO Precis Oncol. 2023;7:e2200294. https:\/\/doi.org\/10.1200\/po.22.00294.","journal-title":"JCO Precis Oncol"},{"key":"416_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107970","volume":"197","author":"D-W Kang","year":"2024","unstructured":"Kang D-W, Park S-K, Kang S, Lee E-K. Cost-effectiveness of next-generation sequencing for advanced EGFR\/ALK-negative non-small cell lung cancer. Lung Cancer. 2024;197:107970. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107970.","journal-title":"Lung Cancer"},{"issue":"6","key":"416_CR111","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","volume":"98","author":"S Behjati","year":"2013","unstructured":"Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013;98(6):236\u20138. https:\/\/doi.org\/10.1136\/archdischild-2013-304340.","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"1","key":"416_CR112","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health"},{"issue":"7","key":"416_CR113","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/13696998.2018.1450261","volume":"21","author":"AA Dalal","year":"2018","unstructured":"Dalal AA, Guerin A, Mutebi A, Culver KW. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. J Med Econ. 2018;21(7):649\u201355. https:\/\/doi.org\/10.1080\/13696998.2018.1450261.","journal-title":"J Med Econ"},{"issue":"2","key":"416_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002230","volume":"14","author":"A Hamblin","year":"2017","unstructured":"Hamblin A, Wordsworth S, Fermont JM, et al. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: retrospective validation and prospective audit in the UK National Health Service. PLoS Med. 2017;14(2):e1002230. https:\/\/doi.org\/10.1371\/journal.pmed.1002230.","journal-title":"PLoS Med"},{"issue":"1","key":"416_CR115","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1080\/07853890.2021.1956687","volume":"53","author":"W Pipitprapat","year":"2021","unstructured":"Pipitprapat W, Pattanaprateep O, Iemwimangsa N, et al. Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma. Ann Med. 2021;53(1):1244\u201356. https:\/\/doi.org\/10.1080\/07853890.2021.1956687.","journal-title":"Ann Med"},{"issue":"4","key":"416_CR116","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jmoldx.2021.01.004","volume":"23","author":"M van de Ven","year":"2021","unstructured":"van de Ven M, Koffijberg H, Retel V, et al. Real-world utilization of biomarker testing for patients with advanced non-small cell lung cancer in a tertiary referral center and referring hospitals. J Mol Diagn. 2021;23(4):484\u201394. https:\/\/doi.org\/10.1016\/j.jmoldx.2021.01.004.","journal-title":"J Mol Diagn"},{"issue":"1","key":"416_CR117","doi-asserted-by":"publisher","DOI":"10.1177\/2381468318821103","volume":"4","author":"L Asphaug","year":"2019","unstructured":"Asphaug L, Melberg HO. The cost-effectiveness of multigene panel testing for hereditary breast and ovarian cancer in Norway. MDM Policy Pract. 2019;4(1):2381468318821103. https:\/\/doi.org\/10.1177\/2381468318821103.","journal-title":"MDM Policy Pract"},{"issue":"4","key":"416_CR118","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cyt.13485","volume":"36","author":"P Pisapia","year":"2025","unstructured":"Pisapia P, Iaccarino A, Troncone G, Malapelle U. Liquid biopsy in solid tumours: an overview. Cytopathology. 2025;36(4):296\u2013302. https:\/\/doi.org\/10.1111\/cyt.13485.","journal-title":"Cytopathology"},{"key":"416_CR119","doi-asserted-by":"publisher","unstructured":"Malapelle U, Fusco N, Pisapia P, Pagni F. From traditional histology to next-generation pathology: a review of the workflow for the characterisation and molecular profiling of non-small cell lung cancer samples. EMJ Oncology. 2020. https:\/\/doi.org\/10.33590\/emjoncol\/19-00107.","DOI":"10.33590\/emjoncol\/19-00107"},{"issue":"2","key":"416_CR120","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","volume":"24","author":"LE Raez","year":"2023","unstructured":"Raez LE, Brice K, Dumais K, et al. Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC). Clin Lung Cancer. 2023;24(2):120\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2022.11.007.","journal-title":"Clin Lung Cancer"},{"key":"416_CR121","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2020.10.012","volume":"152","author":"F Griesinger","year":"2021","unstructured":"Griesinger F, Eberhardt W, Nusch A, et al. Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315). Lung Cancer. 2021;152:174\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2020.10.012.","journal-title":"Lung Cancer"},{"issue":"7","key":"416_CR122","first-page":"3979","volume":"35","author":"M Sandelin","year":"2015","unstructured":"Sandelin M, Berglund A, Sundstr\u00f6m M, et al. Patients with non-small cell lung cancer analyzed for EGFR: adherence to guidelines, prevalence and outcome. Anticancer Res. 2015;35(7):3979\u201385.","journal-title":"Anticancer Res"},{"key":"416_CR123","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","volume":"154","author":"KM Kerr","year":"2021","unstructured":"Kerr KM, Bibeau F, Thunnissen E, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer. 2021;154:161\u201375. https:\/\/doi.org\/10.1016\/j.lungcan.2021.02.026.","journal-title":"Lung Cancer"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00416-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:44:36Z","timestamp":1773668676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00416-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00416-z","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (Jamie P. Grossman, Elizabeth A. Sheppard, Zhuofan Yan, Magdalene Crabbe and Yogesh S. Punekar) declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No patient-level data of a personal or sensitive nature were included in this research, and therefore approvals from institutional review boards or independent ethics committees were not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}